Avant's Collateral Advantage for Global Health
This article was originally published in Start Up
Executive Summary
Avant Immunotherapeutics is contributing to social good by leveraging the assets it has-namely, a portfolio of intellectual property for making single-dose vaccines that don't require refrigeration. The firm's good works also happen to make good business sense.